In the second half of the pharmaceutical industry will stage two "play", pharmaceutical machine companies ready to take over?

"Pharmaceutical network market analysis" in the second half of this year, the third batch of volume procurement, 2020 version of the health insurance catalog negotiations are undoubtedly the pharmaceutical industry's "play", and therefore by the industry's attention.
for the pharmaceutical industry, with the promotion of policies such as the normalization of collection, consistent evaluation and medical insurance negotiations, the pharmaceutical market pattern has accelerated and the industry is facing transformation and upgrading.
, the pharmaceutical equipment industry, as the upper reaches of the pharmaceutical industry, will also usher in new opportunities and challenges.
so, are pharmaceutical companies ready to take over? The pharmaceutical industry will stage two "play" the third batch of production procurement will be launched on August 20 this year, this time involving 56 varieties, 86 standard drugs, including omeprazole, metformin, amoxilin and other common drugs.
it is worth noting that the third batch of selected varieties, including a number of large varieties, and a large number of manufacturers.
For example, metformin oral regular release dosage form currently over-evaluated, including North China Pharmaceuticals, Shipharma Yio, Ha Pharmaceutical Group Pharmaceuticals six factories, Shanghai Xinyi Balance Pharmaceuticals, Yiling Pharmaceuticals, etc. a total of more than 20 enterprises;
addition, there are about 19 reviewers of Catople films.
estimated that the total annual sales of 56 varieties of more than one billion varieties of nearly 60 billion yuan, the industry generally believes that the third batch of collection price reduction will be greater.
, in order to compete for market share in exchange for price, competition will become more intense.
2020 version of the health care directory adjustment curtain is also about to open.
the general direction of this adjustment, the industry believes that more innovative drugs, including domestic new drugs and imported new drugs will have the opportunity to be included in health insurance.
For example, medicines referred to in article 3 to be included in the list of new drugs in urgent clinical need abroad, to encourage generic drug catalogues or to encourage research and development to declare children's medicines, which have been approved for market by the State Drug Administration by 31 December 2019;
The adjustment also explicitly included the "second batch of state-organized drug centralized procurement of selected drugs" into the health insurance catalog, and the main purpose of the collection is to reduce drug prices through price-for-volume, while helping to support and encourage those low-value generic enterprises to change and upgrade in the direction of innovation, and promote the development of innovative drug industry.
it is not difficult to see that innovative drugs as a whole will benefit, the future release will be accelerated.
market had earlier worried about the impact on drug companies of volume-buying and lower prices for the new health-care catalog.
, according to IQVIA, total hospital drug sales in China grew 9.4% year-on-year in 2019, up from 3.5% in 2019.
however, in the second half of 2019, due to the impact of collection and health care negotiations and the implementation of policies, product prices fell, china's hospital drug market growth slowed, in the fourth quarter of 2019 year-on-year growth rate of 6%.
from the response of some pharmaceutical companies on the interactive platform, many pharmaceutical companies said that the impact on performance is small, and some varieties because of the failure to win the bid or withdraw from health insurance to bring a decline in corporate profits.
In view of the impact of this collection on pharmaceutical companies, especially listed pharmaceutical companies, some people in the industry believe that, in view of the performance of the first two rounds of national collection and mining winning and unsealed enterprises, the winning enterprise has the advantage of raw material drug cost, the winning variety in the case of low market share before winning the bid, preparation profitability and cash flow situation It is expected to improve, while the large varieties of the stock of enterprises that have not won the bid will be affected by the medical insurance balance and local collection policies, the market space will be gradually reduced, and some people believe that the collection is conducive to reducing the promotion costs and sales costs of enterprises, suitable for some domestic "barefoot" enterprises corner overdive, can focus on more varieties of enterprises.
pharmaceutical machine enterprises ready to pick up the overall view, in the collection of normal, pharmaceutical companies are not so panicked, but the specific situation, but also to see when the real implementation of the situation.
is that the pharmaceutical market competition is becoming more and more intense, the industry shuffle is accelerating, innovation is becoming a development trend.
the pharmaceutical industry is facing innovation and upgrading, as the pharmaceutical industry upstream of the pharmaceutical equipment industry will also usher in new opportunities and challenges.
opportunities, with the upgrading of people's consumption level, aging, as well as health insurance, collection policies, driven by drug prices, reduce the burden of patient costs, the pharmaceutical market is expected to accelerate the expansion of capacity, drive the pharmaceutical industry and pharmaceutical equipment market development, high-end pharmaceutical products demand or further enhance.
, pharmaceutical equipment will play a crucial role in the demand for capacity expansion and cost-effectiveness for pharmaceutical companies, especially those that collect winning bids and enter health insurance.
that in order to help the healthy development of the pharmaceutical health industry, some pharmaceutical machinery enterprises have been laid out.
example, in response to the demand for capacity upgrading faced by the winning pharmaceutical companies under the belt purchase, pharmaceutical machine enterprises exhibited the overall solution of the centralized water supply of the pharmaceutical "4 plus 7" at the 58th Pharmaceutical Machine Show.
the solution is designed to improve water quality, reduce production and operating costs and improve the competitiveness of pharmaceutical companies, according to its field leaders.
In a general term, in the pharmaceutical enterprises continue to "take advantage of the wind and waves" background, the pharmaceutical equipment industry also needs to keep pace with the times, timely pulse market trends, proactively grasp the new needs of customers, through continuous innovation and upgrading, to help pharmaceutical companies to put good production quality, production capacity and so on.
.